Medtronic has announced the results from a new observational study that showed its Nellcor Bedside SpO2 Patient Monitoring System delivers faster stable oxygen saturation readings than Masimo Radical-7 Pulse CO-Oximeter in newborns.
A simple, non-invasive bedside test, pulse oximetry can precisely identify the percentage of blood saturated with oxygen and measure heart rate.
The independent, prospective observational study compared the efficacy and reliability of these two pulse oximeters, both set at the highest sensitivity, with electrocardiography (ECG) monitoring after the delivery of 60 term newborns by Caesarian section.
Study results showed that a stable signal was obtained from all 60 newborns with the Nellcor pulse oximeter while from only 55 newborns with the Masimo pulse oximeter.
In addition, of the 55 newborns with stable signals from both monitors, the mean time to stable signal with Nellcor pulse oximeter was 15 seconds versus 27 seconds with Masimo pulse oximeter.
In the study, ECG showed a heart rate greater than 100 beats per minute (BPM) versus lower than 100BPM with Masimo monitor, which may be seen as false bradycardia.
In 16 of the 51 newborns, the difference in heart rate with the Masimo monitor was ³40BPM versus the comparator ECG.
Furthermore, the heart rate detected by Nellcor pulse oximetry monitor matched closely with the ECG, with no false bradycardia and reading having greater than 40BPM difference versus the ECG was recorded.
Medtronic Minimally Invasive Therapies Group Patient Monitoring president Frank Chan said: “A newborn’s heart rate is a key component of physician assessment for resuscitation and helps to identify not only those in need of intervention but also their response to treatment.
“This study demonstrates that physicians can rely on Nellcor pulse oximetry technology to post data quickly, offer consistency, perform well with these patients, and meet the requirements of the neonatal resuscitation program guidelines, which are especially important in the delivery room.”
In December, Medtronic launched its neonatal acute dialysis machine in the US to treat paediatric patients who need renal replacement therapy.